SEARCH:   Advanced

Blood, 1 March 2005, Vol. 105, No. 5, pp. 2189-2197. Prepublished online as a Blood First Edition Paper on November 2, 2004; DOI 10.1182/blood-2004-07-2757. This Article Full Text (PDF) All Versions of this Article: 2004-07-2757v1 105/5/2189    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Chilton, P. M Articles by Ildstad, S. T Search for Related Content PubMed PubMed Citation Articles by Chilton, P. M Articles by Ildstad, S. T Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted July 20, 2004 Accepted October 14, 2004 Hematopoietic stem cells from NOD mice exhibit autonomous behavior and a competitive advantage in allogeneic recipients Paula M Chilton, Francine Rezzoug, Mariusz Z Ratajczak, Isabelle Fugier-Vivier, Janina Ratajczak, Magda Kucia, Yiming Huang, Michael K Tanner, and Suzanne T Ildstad* Institute for Cellular Therapeutics, University of Louisville, Louisville, KY, USA * Corresponding author; email: suzanne.ildstad{at}louisvile.edu. Type 1 diabetes is a systemic autoimmune disease that can be cured by transplantation of HSC from disease-resistant donors. NOD mice have a number of features that distinguish them as BMT recipients that must be understood prior to the clinical application of chimerism to induce tolerance. In the present studies, we characterized NOD HSC, comparing their engraftment characteristics to HSC from disease-resistant strains. Strikingly, NOD HSC are significantly enhanced in engraftment-potential compared to HSC from disease-resistant donors. Unlike HSC from disease-resistant strains, they do not require graft facilitating cells to engraft in allogeneic recipients. Additionally, they exhibit a competitive advantage when co-administered with increasing numbers of syngeneic HSC, produce significantly more CFU-S in vivo in allogeneic recipients, and more CFU-GM in vitro compared to HSC from disease-resistant controls. NOD HSC also exhibit significantly enhanced chemotaxis to an SDF-1 gradient and adhere significantly better on primary stroma. This enhanced engraftment-potential maps to the Idd9 locus, and as such the TNF receptor family as well as ski/sno genes may be involved in the mechanism underlying the autonomy of NOD HSC. These findings may have important implications to understand the evolution of autoimmune disease and impact upon potential strategies for cure. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: W. F. N. Chan, H. Razavy, B. Luo, A. M. J. Shapiro, and C. C. Anderson Development of Either Split Tolerance or Robust Tolerance along with Humoral Tolerance to Donor and Third-Party Alloantigens in Nonmyeloablative Mixed Chimeras J. Immunol., April 15, 2008; 180(8): 5177 - 5186. [Abstract] [Full Text] [PDF]

	Copyright © 2004 by American Society of Hematology         Online ISSN: 1528-0020